- JYNNEOS vaccine safety monitoring in the Republic of Korea, 2022: a cross-sectional study
-
Jaeeun Lee, Seunghyun Lewis Kwon, Jinhee Park, Hyuna Bae, Hyerim Lee, Geun-Yong Kwon
-
Osong Public Health Res Perspect. 2023;14(5):433-438. Published online October 18, 2023
-
DOI: https://doi.org/10.24171/j.phrp.2023.0182
-
-
1,570
View
-
51
Download
-
4
Web of Science
-
3
Crossref
-
 Graphical Abstract
 Abstract
 PDF
 - Objectives
With the recent global mpox outbreak, the JYNNEOS vaccine (Modified Vaccinia Ankara-Bavarian Nordic) was developed as a third-generation smallpox vaccine and initially favored for mpox immunization. Vaccine-associated side effects contribute to vaccine hesitancy. Consequently, tracking adverse events post-immunization is crucial for safety management. This study used data from the national active vaccine safety surveillance conducted in Korea from August 25 to November 24, 2022 to detect potential safety signals and adverse events. Methods: Data on health conditions following vaccination were gathered from web-based surveys and reported via active surveillance through the Immunization Registry Information System. This follow-up system functioned via a text message link, surveying adverse events and health conditions beginning on the second day post-vaccination. Information about specific adverse events, including both local and systemic reactions, was collected. Results: The study included 86 healthcare workers who had received at least 1 dose of the JYNNEOS vaccine. Among the respondents, 79.1% reported experiencing at least 1 adverse event, with the majority being local reactions at the injection site. The incidence of adverse events was higher following the first dose (67.9%) than after the second dose (34.4%). The most frequently reported adverse event for both doses was mild pain at the injection site. Conclusion: The study provides crucial information on the safety of the JYNNEOS vaccine, demonstrating that most adverse events were manageable and predominantly localized to the injection site. Nonetheless, additional research is needed on the safety of various vaccine administration techniques and the vaccine’s effects on broader demographics.
-
Citations
Citations to this article as recorded by  - Adverse Reactions After Intradermal Vaccination With JYNNEOS for Mpox in Korea
So Yun Lim, Yu Mi Jung, Yeonjae Kim, Gayeon Kim, Jaehyun Jeon, BumSik Chin, Min-Kyung Kim
Journal of Korean Medical Science.2024;[Epub] CrossRef - First Nationwide Mpox Vaccination Program in the Republic of Korea: Implications for an Enhanced Public Health Response
Seunghyun Lewis Kwon, Minju Song, Wonkyung Lee, Jeeyeon Shin, Su-Yeon Lee, Sang-Gu Yeo, Minjeong Kim, Sanggyun Jeong, Joonku Park, Dongwoo Lee, Sookyoung Lim
Journal of Korean Medical Science.2024;[Epub] CrossRef - Global perspectives on smallpox vaccine against monkeypox: a comprehensive meta-analysis and systematic review of effectiveness, protection, safety and cross-immunogenicity
Hao Liu, Wenjing Wang, Yang Zhang, Fuchun Wang, Junyi Duan, Tao Huang, Xiaojie Huang, Tong Zhang
Emerging Microbes & Infections.2024;[Epub] CrossRef
- The first reported hepatitis E outbreak in a food manufacturing factory: Korea, 2022
-
Hansol Yeom, Soonryu Seo, Youngsil Yoon, Jaeeun Lee, Myung-Guk Han, Deog-Yong Lee, Sun-Whan Park, Song A Park, Sook-Hyang Jeong, Jin Gwack
-
Osong Public Health Res Perspect. 2023;14(1):15-22. Published online February 22, 2023
-
DOI: https://doi.org/10.24171/j.phrp.2022.0305
-
-
Graphical Abstract
Abstract
PDF
 - Objectives
On February 16, 2022, 12 cases of hepatitis E virus (HEV) infection were reported in a food manufacturing factory in Korea. The aim of this study was to identify additional cases and to determine the source of this HEV outbreak. Methods: This study was an in-depth investigation of 12 HEV immunoglobulin M (IgM)-positive cases and their demographic, clinical, and epidemiological characteristics. On-site specimens were collected from the environment and from humans, and a follow-up investigation was conducted 2 to 3 months after the outbreak. Results: Among 80 production workers in the factory, 12 (15.0%) had acute HEV infection, all of whom were asymptomatic. The follow-up investigation showed that 3 cases were HEV IgMpositive, while 6 were HEV IgG-positive. HEV genes were not detected in the HEV IgM-positive specimens. HEV genes were not detected in the food products or environmental specimens collected on-site. HEV was presumed to be the causative pathogen. However, it could not be confirmed that the source of infection was common consumption inside the factory. Conclusion: This was the first domestic case of an HEV infection outbreak in a food manufacturing factory in Korea. Our results provide information for the future control of outbreaks and for the preparation of measures to prevent domestic outbreaks of HEV infection.
|
